Tiragolumab
Based on 1 Customer Validation
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.04%
- CAS 番号: 1918185-84-8
- 分子量:148.66 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-P99202
VibostolimabAnti-TIGIT mAb -
HY-P99156
RelatlimabLAG-3 Inhibitor -
HY-P99044
SabatolimabTIM-3 Antibody -
HY-P99763
OciperlimabAnti-TIGIT Antibody -
HY-P9901
IpilimumabCTLA-4 Inhibitor -
HY-P99001
Human IgG1 kappa, Isotype ControlIgG1κ Isotype Control -
HY-P99029
MagrolimabAnti-CD47 Antibody -
HY-P9904
AtezolizumabAnti-PD-L1 Antibody -
HY-15531
VenetoclaxBCL-2 Inhibitor -
HY-P99003
Human IgG4 (S228P) kappa, Isotype ControlIgG4κ Isotype Control -
HY-P99858
DomvanalimabAnti-TIGIT Antibody -
HY-P9903
NivolumabPD-1 Inhibitor
生物活性
製品説明
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
TIGIT
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Tiragolumab has a significant ADCP effect on CHO-K1/TIGIT cells in a dose-dependent manner.The EC50 for this effect is 189.43 ng/mL.
化学情報
-
CAS 番号 1918185-84-8
-
性状 Liquid
-
分子量 148.66 kDa
-
Color Colorless to light yellow
-
SMILES
[Tiragolumab]
-
別名
MTIG-7192A; RG-6058
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Houssaini MS, et al. Advances in the management of non-small cell lung cancer (NSCLC): A new practice changing data from asco 2020 annual meeting. Cancer Treat Res Commun. 2020;25:100239. [Content Brief]
[2]. Caruso C. Tiragolumab Impresses in Multiple Trials. Cancer Discov. 2020 Aug;10(8):1086-1087. [Content Brief]
[3]. Shen X, et al. TIGIT-Fc Promotes Antitumor Immunity. Cancer Immunol Res. 2021 Sep;9(9):1088-1097. [Content Brief]
[4]. Dai T, et al. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody. Sci Rep. 2024 May 9;14(1):10661. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Tiragolumab 関連分類
HY-P9986 関連分類
Powered by Bioz